Trials / Recruiting
RecruitingNCT05188885
A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 90,000 (estimated)
- Sponsor
- Guangdong Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Chronic kidney disease (CKD) refers to a variety of different diseases characterized by impairment of kidney structure and/or renal function. The prevalence of CKD in China is as high as 10.8%. With a population of more than 150 million, China has the largest number of CKD patients all over the world. People with CKD would not only progress to uremia and need renal replace treatment, it also significantly increases risk of cardiovascular disease than non-CKD population. It has created a heavy burden on people's health and national economy. There is an urgent need to establish an effective system for CKD prevention and control in China. Evidences from large sample cohort and real world based research are still rare. This study will provide good experience for reducing the occurrence and development of CKD.
Detailed description
This study is designed as an investigator-initiated, multi-center, prospective and observational real world study based on mainland Chinese population. The investigators aimed to investigate the occurrence, development, treatment, prognosis state and related risk factors of CKD in China. This study based on the standardized data network, which provides efficient data collection, integration and analysis for researchers and clinicians in multi-centers. The sample size of this study was estimated by statisticians, epidemiologists and clinicians. Real-world studies adopted an open standard for inclusion and exclusion, larger sample size could cover a wider group of patients and take the possibility of loss of follow-up into account. Subgroup analysis can be performed in a heterogeneous population and expand the significance of the study.
Conditions
Timeline
- Start date
- 2021-12-27
- Primary completion
- 2026-12-27
- Completion
- 2028-12-27
- First posted
- 2022-01-12
- Last updated
- 2026-01-15
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05188885. Inclusion in this directory is not an endorsement.